PPARs in atherosclerosis: the clot thickens

被引：32

作者：

Castrillo, A

Tontonoz, P

机构：

[1] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2004年 / 114卷 / 11期

关键词：

D O I：

10.1172/JCI200423705

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Cardiovascular disease is the leading cause of morbidity and mortality in Western countries. Previous studies have highlighted the beneficial effects of PPARgamma activators on cardiovascular disease; however, the role of other PPAR family members in atherosclerosis is less clear. A report in this issue of the JCI expands our understanding of PPARs in vascular biology and highlights the potential use of multiple PPAR agonists to limit lipid accumulation in macrophages (see the related article beginning on page 1564).

引用

页码：1538 / 1540

页数：3

共 19 条

[1] Nuclear receptors in macrophage biology: At the crossroads of lipid metabolism and inflammation
Castrillo, A
Tontonoz, P
[J]. ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2004, 20 : 455 - 480
[2] A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
Chawla, A
Boisvert, WA
Lee, CH
Laffitte, BA
Barak, Y
Joseph, SB
Liao, D
Nagy, L
Edwards, PA
Curtiss, LK
Evans, RM
Tontonoz, P
[J]. MOLECULAR CELL, 2001, 7 (01) : 161 - 171
[3] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
Chinetti, G
Lestavel, S
Bocher, V
Remaley, AT
Neve, B
Torra, IP
Teissier, E
Minnich, A
Jaye, M
Duverger, N
Brewer, HB
Fruchart, JC
Clavey, V
Staels, B
[J]. NATURE MEDICINE, 2001, 7 (01) : 53 - 58
[4] Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice
Collins, AR
Meehan, WP
Kintscher, U
Jackson, S
Wakino, S
Noh, G
Palinski, W
Hsueh, WA
Law, RE
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) : 365 - 371
[5] Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice
Duez, H
Chao, YS
Hernandez, M
Torpier, G
Poulain, P
Mundt, S
Mallat, Z
Teissier, E
Burton, CA
Tedgui, A
Fruchart, JC
Fiévet, C
Wright, SD
Staels, B
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) : 48051 - 48057
[6] Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Joseph, SB
McKilligin, E
Pei, LM
Watson, MA
Collins, AR
Laffitte, BA
Chen, MY
Noh, G
Goodman, J
Hagger, GN
Tran, J
Tippin, TK
Wang, XP
Lusis, AJ
Hsueh, WA
Law, RE
Collins, JL
Willson, TM
Tontonoz, P
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (11) : 7604 - 7609
[7] Transcriptional repression of atherogenic inflammation:: Modulation by PPARδ
Lee, CH
Chawla, A
Urbiztondo, N
Liao, D
Boisvert, WA
Evans, RM
[J]. SCIENCE, 2003, 302 (5644) : 453 - 457
[8] Peroxisome proliferator-activate inhibit development of atherosclerosis in LDL receptor-deficient mice
Li, AC
Brown, KK
Silvestre, MJ
Willson, TM
Palinski, W
Glass, CK
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) : 523 - 531
[9] Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and β
Li, AC
Binder, CJ
Gutierrez, A
Brown, KK
Plotkin, CR
Pattison, JW
Valledor, AF
Davis, RA
Willson, TM
Witztum, JL
Palinski, W
Glass, CK
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) : 1564 - 1576
[10] Atherosclerosis
Lusis, AJ
[J]. NATURE, 2000, 407 (6801) : 233 - 241

← 1 2 →